# Phase IC Study of Safety and PK of SQ109 300mg Daily

> **NCT01358162** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **OTHER:** Placebo
- **DRUG:** SQ109

## Key facts

- **NCT ID:** NCT01358162
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358162, "Phase IC Study of Safety and PK of SQ109 300mg Daily". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01358162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*